Trypanosomal type I nitroreductase (NTR1)

Trypanosomal type I nitroreductase (NTR1) is a flavin-dependent enzyme essential for the activation of nitroheterocyclic prodrugs used to treat kinetoplastid infections (Wilkinson et al., 2008, PubMed: 18463605). Found in parasites such as Trypanosoma brucei and Trypanosoma cruzi, this enzyme is characterized as oxygen-insensitive, meaning it performs a series of two-electron reductions on nitro groups (UniProt: Q388L1). This process converts relatively non-toxic compounds like nifurtimox, benznidazole, and fexinidazole into highly reactive and cytotoxic intermediates, including nitrenium ions, which induce DNA damage and protein dysfunction (Hall & Wilkinson, 2012, PubMed: 22544451). Because humans lack a functional equivalent of the Type I nitroreductase, the enzyme serves as a critical basis for the selective toxicity of these antiparasitic agents. However, the clinical utility of these drugs is often threatened by the emergence of resistance, frequently mediated by the loss or downregulation of the NTR1 gene (Wyllie et al., 2016, PubMed: 27151875). Understanding the structural and functional nuances of this enzyme is vital for developing next-generation nitro-compounds with improved efficacy and safety profiles.

Other names

Type I nitroreductaseOxygen-insensitive nitroreductaseNTRNTR1Trypanosomal nitroreductase

The enzyme catalyzes the two-electron reduction of nitroheterocyclic prodrugs into reactive, toxic intermediates such as nitrenium ions and hydroxylamines, which cause oxidative stress and DNA damage within the parasite (Wilkinson et al., 2008, PubMed: 18463605).